View Older Stories View More Recent Stories
-
Novo Nordisk (NVO) call put ratio 2.3 calls to 1 put with a focus as share price up 8.5%
-
Novo Nordisk's oral Wegovy reaches 3,071 prescriptions in first four days
-
Novo Nordisk stock target raised at UBS ahead of Wegovy Pill launch
-
BMO Capital: 'Novo Nordisk (NVO) Aims to Regain Obesity Leadership as Orals Expand Market'
-
Novo Nordisk CEO warns of international competition headwinds, cites Lilly
-
Novo Nordisk (NVO) EVP for product and portfolio strategy: market for oral weight-loss drugs versus injectables bigger than originally thought
-
Amazon Pharmacy adds Novo Nordisk's Wegovy pill with insurance coverage
-
Novo Nordisk (NVO) call put ratio 1.9 calls to 1 put into the annual J.P. Morgan Healthcare Conference
-
Novo Nordisk's (NVO) U.S. public affairs head departs - Reuters
-
Novo Nordisk launches oral Wegovy pill for weight loss across US
-
China's top court upholds Novo Nordisk semaglutide patent validity
-
Novo Nordisk reportedly cut Wegovy prices in China by half
-
Popular stocks with increasing option volume: NVO MU FITB MSTR ORCL RKLB WMT INTC AVGO HOOD
-
BMO Capital on Novo Nordisk (NVO): 'FDA Approval Brings Much-Needed Cheer'
-
ZIM, Novo Nordisk rise in premarket, space stocks fall
-
Novo Nordisk shares jump after FDA approves first GLP-1 weight-loss pill
-
Novo Nordisk (NVO) call put ratio 3.6 calls to 1 put into FDA approval of Wegovy in weight loss
-
Novo Nordisk's Wegovy pill wins FDA approval as first oral GLP-1 for weight loss
-
Here's the list of top biotech stocks to own for 2026
-
Trump to announce prescription drug price agreements
-
White House: Trump on Friday to announce more 'deals that will lower prices of drugs and pharmaceuticals'
-
BMO Capital Reiterates Outperform Rating on Eli Lilly (LLY)
-
BofA Comments on GLP-1s and Potential Pressure Ahead
-
Novo Nordisk (NOVOB:DC) (NVO) PT Lowered to DKK430 at Kepler Cheuvreux
-
This EU pharma stock offers 'unmatched' re-rating potential: analyst
-
EMA committee backs higher dose Wegovy for greater weight loss
-
Novo Nordisk completes $4.7 billion acquisition of Akero Therapeutics
-
Argus Downgrades Novo Nordisk (NVO) to Hold
-
Novo Nordisk (NVO) preparing to launch Ozempic in India in December - Reuters
-
UK and US poised to agree zero-tariffs deal on pharmaceuticals - The Times
-
What comes next for Eli Lilly (LLY) stock after $1T valuation?
-
Novo Nordisk submits application for higher dose semaglutide
-
Bernstein on IRA pricing: $245 really is the floor
-
Novo Nordisk reports positive phase 2 results for diabetes drug amycretin
-
Novo Nordisk (NVO) call put ratio 1.6 calls to 1 put amid wide price movement
-
Novo Nordisk (NVO) PT Lowered to $46 at BMO Capital
-
HSBC Downgrades Novo Nordisk (NOVOB:DC) (NVO) to Hold
-
Biogen to gain from Novo Nordisk Alzheimer’s failure, says Jefferies
-
Bernstein on Novo's Alzheimer's miss: 'Don't expect Lilly to stay quiet'
-
Novo Nordisk shares sink after Alzheimer’s drug trial failure
-
Novo Nordisk semaglutide fails to slow Alzheimer's disease in phase 3 trials
-
Septerna's (SEPN) Novo Pursuing a Multi-Billion-Dollar Opportunity- Cantor Fitzgerald
-
KeyBanc: White House GLP-1 Deals Boost Growth Potential for Key Suppliers
-
BMO Capital: 'Extraordinary General Meeting Sets the Stage for Novo Nordisk (NVO) Transformation'
-
Novo Nordisk cuts cash prices for Wegovy and Ozempic to $199 monthly
-
Mikael Dolsten withdraws board candidacy at Novo Nordisk
-
Mangoceuticals clarifies GLP-1 weight-management program launch
-
Lilly and Novo Nordisk say no affiliation with Mangoceuticals (MGRX)
-
Novo Nordisk cuts Wegovy price by as much as 33% in India - Reuters
-
Novo Nordisk shows semaglutide benefits in liver disease with minimal weight loss

